Results 151 to 160 of about 41,743 (197)

Efficacy and Safety of Tofacitinib Compared to Cyclophosphamide in Early Diffuse Cutaneous Systemic Sclerosis: A Randomized Controlled Trial. [PDF]

Cureus
Amin Khan N, Islam A, Shahin A, Jamil Abdal S, Haq SA.   +4 more
europepmc   +1 more source

Biologic dose escalation in inflammatory bowel disease in the United States. [PDF]

J Manag Care Spec Pharm
Chapman C, Vadhariya A, Bires N, Brady BL, Creveling T, Ross R, Evans KA, Panni T, Chan-Diehl FW, McGinnis K.   +9 more
europepmc   +1 more source

REAL-WORLD EXPERIENCE WITH JANUS KINASE INHIBITORS IN EXTRAINTESTINAL MANIFESTATIONS AND INFLAMMATORY BOWEL DISEASE IN COLOMBIA: A COMPARATIVE STUDY (JAKEIM-IBD STUDY). [PDF]

Arq Gastroenterol
Parra-Izquierdo V, Ardila O, Márquez JR, Riveros J, Gómez-Venegas ÁA, Medrano-Almanza CA, Ballesteros M, Barreto-Pérez J, Frias-Ordoñez JS.   +8 more
europepmc   +1 more source

From concept to practice: real-world safety of JAK inhibitors in rheumatoid arthritis treatment. [PDF]

Front Med (Lausanne)
Bonfiglioli KR.
europepmc   +1 more source

Oral JΑΚ Inhibitors in Vitiligo Treatment. [PDF]

Dermatol Ther (Heidelb)
Panagopoulou A, Sotiriou E, Papadimitriou I, Pavlidis A, Bakirtzi K, Tsentemeidou A, Arabatzis M, Vakirlis E, Kiritsi D.   +8 more
europepmc   +1 more source

Upadacitinib in refractory ulcerative colitis patients with high thromboembolic risk: two case reports. [PDF]

Front Immunol
Mo R, Yu S, Xu H, Hao J.
europepmc   +1 more source

Towards New Strategies: Case Report and Review of the Literature-Effective Use of JAK Inhibitor Baricitinib in a 4-Year-Old Boy with Anti-MDA5 Antibody-Positive Juvenile Dermatomyositis. [PDF]

J Clin Med
Buzoianu O, Satirer Ö, Kuemmerle-Deschner JB, Reiser C.   +3 more
europepmc   +1 more source

Refractory Livedoid Vasculopathy Successfully Treated with Hyperbaric Oxygen Therapy and Tofacitinib. [PDF]

Indian Dermatol Online J
Mani S, Rout A, Kumar S, Upadhyay A, Kothari R, Doley N.   +5 more
europepmc   +1 more source

Infectious retinitis associated with JAK inhibitors: the ongoing duality of JAK inhibitors. [PDF]

Int J Retina Vitreous
Pulido JS, Mano F, Casella M, Ishida S.
europepmc   +1 more source

Pretreatment Cytokine Signatures as Candidate Biomarkers for JAK Inhibitor Response in Anti-MDA5 Dermatomyositis-Related Interstitial Lung Disease: A Pilot Study. [PDF]

ACR Open Rheumatol
Matsuo H, Koga T, Shimizu T, Ide H, Koto S, Kojima K, Fujita Y, Okamoto M, Takatani A, Suzuki T, Matsushita Y, Kawakami A.   +11 more
europepmc   +1 more source